Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 6/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.47 |
| ▸ | EED | O75530 | 12/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.34 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL807317 | 0.92 | OPRM1 (0.54) | OPRM1OPRD1OPRK1OPRL1DRD2 | |
| SCHEMBL15084341 | 0.75 | OPRM1 (0.58) | OPRM1OPRD1EEDOPRK1DRD2 | |
| SCHEMBL17084068 | 0.74 | KDM4E (0.47) | EED | |
| SCHEMBL15081980 | 0.74 | EED (0.48) | EED | |
| SCHEMBL15081961 | 0.74 | KDM4E (0.47) | EED | |
| SCHEMBL12384442 | 0.72 | ALDH1A1 (0.53) | OPRM1OPRD1OPRK1DRD2DRD4 | |
| SCHEMBL27306568 | 0.70 | CHRNB2 (0.40) | OPRM1OPRK1OPRL1SLC6A2 | |
| SCHEMBL807487 | 0.70 | OPRM1 (0.55) | OPRM1OPRD1SCN8A | |
| SCHEMBL806942 | 0.70 | OPRM1 (0.55) | OPRM1OPRD1SCN8A | |
| SCHEMBL15081992 | 0.69 | OPRM1 (0.43) | OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242981-B2 | Fused pyrazole derivatives as novel ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-01-26 | — | — | US | disclosed |
| US-20130172341-A1 | FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2013-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172341-A1 | FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS | MAPK1, MAPK3, MAP3K1 | OPRM1 3387/4885OPRD1 2021/4885EED 1580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.